利用左束支区域起搏除颤导线植入系统推进临床心力衰竭结局 (ACHIEVED LBBAP)
推进心力衰竭临床成果:利用除颤导线植入系统进行左束支区域起搏
This 2x2 randomized crossover feasibility study will evaluate the therapeutic value of adding pacing from the left ventricular lead to Left Bundle Branch Area Pacing (LBBAP) using a cardiac resynchronization therapy defibrillator (CRT-D). This combined therapy is known as Left Bundle Branch Optimized Cardiac Resynchronization Therapy (LOT-CRT) and will be compared to LBBAP therapy over sequential 6-month periods in CRT-indicated patients with LBBB. Primary and secondary outcomes are echocardiographic changes. Exploratory assessments will include NT-proBNP and subject-reported quality of life (KCCQ). An observational treatment arm will include subjects who have not been randomized due to unsuccessful implant for real-world observational analysis
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Robert Stadler
- 电话号码:763-526-0261
- 邮箱:robert.stadler@medtronic.com
学习地点
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55407
- 招聘中
- Minneapolis Heart Institute Foundation
-
首席研究员:
- John Zakaib
-
接触:
- Ellen Thomas
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Subject meets current ACC/AHA/HRS guidelines for implantation of a CRT-D device.
- Subject has documented LVEF ≤ 35% within 60 days of enrollment.
- Subject meets the criteria for presence of Strauss-defined LBBB.
- Subject meets NYHA classification II or III.
- Subject is willing and able to provide written consent.
- Subject is at least 18 years of age at the time of consent.
- Subject is geographically stable and willing and able to complete study procedures, including follow-up visits.
- The subject's medical records must be accessible by the enrolling site over the follow-up period.
Exclusion Criteria:
- Subject has documented myocardial infarction before enrollment.
- Subject has non-LBBB conduction patterns such as Right Bundle Branch Block (RBBB) or non-specific IVCD.
- Subject has 2nd or 3rd degree AV block.
- Subject has persistent or permanent atrial fibrillation (AF) or atrial flutter (AFL).
- Subject has intrinsic (non-paced) QRS duration ≤ 120ms.
- Subject with previous or existing pacemaker (including transvenous and transcatheter pacing system), Implantable Cardioverter Defibrillator (ICD, transvenous) or CRT-D (transvenous) device or leads.
- Subject has contraindications for screw-in transvenous lead placement (e.g., mechanical right heart valve).
- Subject underwent valve surgery within 90 days prior to enrollment.
- Subject is unable or unwilling to undergo baseline CMR imaging, if previously collected CMR images are unavailable or do not meet minimum acceptable criteria.
- Subject is post-heart transplantation or is actively listed on the transplantation list.
- Subject is implanted with a left ventricular assist device (LVAD).
- Subject has severe renal disease.
- Subject is on continuous or uninterrupted infusion (inotropic) therapy for heart failure.
- Subject has complex and uncorrected congenital heart disease.
- Subject has life expectancy of less than 12 months.
- Subject is pregnant or breastfeeding.
- Subject is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, without documented pre-approval from a Medtronic study manager.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Observational Treatment Arm
|
CRT-D programmed for LOT-CRT (LBBAP + LV lead ON) ICD programmed for LBBAP |
|
实验性的:Sequence 1
LBBAP therapy for 6 months followed by LOT-CRT for 6 months |
CRT-D programmed for LBBAP (LV lead OFF) CRT-D programmed for LOT-CRT (LBBAP + LV lead ON) |
|
实验性的:Sequence 2
LOT-CRT for 6 months followed by LBBAP therapy for 6 months |
CRT-D programmed for LBBAP (LV lead OFF) CRT-D programmed for LOT-CRT (LBBAP + LV lead ON) |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Left ventricular ejection fraction (LVEF)
大体时间:Baseline, 6 months, 12 months
|
Change in LVEF assessed by echocardiography during each therapy period (baseline to 6 months, 6 months to 12 months). |
Baseline, 6 months, 12 months
|
|
Left ventricular end-systolic volume (LVESV)
大体时间:Baseline, 6 months, 12 months
|
Change in LVESV assessed by echocardiography during each therapy period (baseline to 6 months, 6 months to 12 months). |
Baseline, 6 months, 12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Left ventricular ejection fraction (LVEF)
大体时间:Baseline, 6 months
|
Change in LVEF assessed by echocardiography from baseline to 6 months |
Baseline, 6 months
|
|
Left ventricular end-systolic volume (LVESV)
大体时间:Baseline, 6 months
|
Change in LVESV assessed by echocardiography from baseline to 6 months. |
Baseline, 6 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.